Latest Breaking News On - Professor li jianyong - Page 1 : vimarsana.com

Cambridge: AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in China for the treatment of adult patients with chronic.

Dave fredricksonLi jianyongNational medical products administrationJiangsu provinceExecutive vice presidentOncology business unitAstrazeneca newsLymphocytic leukaemiaProfessor li jianyong